Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
复制标题
DOI：
10.1177/1352458514555785
复制
发表时间：
2015-06
期刊：
影响因子：
--
通讯作者：
Saiz A
中科院分区：
文献类型：
--
作者：
Höftberger R;Sepulveda M;Armangue T;Blanco Y;Rostásy K;Calvo AC;Olascoaga J;Ramió-Torrentà L;Reindl M;Benito-León J;Casanova B;Arrambide G;Sabater L;Graus F;Dalmau J;Saiz A
我们的目的是报告抗髓磷脂少突胶质细胞糖蛋白（MOG-AB）的频率和意义。
从174例患者（48例NMO，84例纵向广泛的脊髓炎（LETM），39个视神经炎（ON）和3个急性散布的脑脊髓炎（ADEM）最初与A隔离的LETM一起呈现）的样本。基于细胞的测定。
在17例（9.8％）患者中发现了MOG-AB，AQP4-AB在59例（34％）中，两种抗体为两种（1.1％）。在17例单独使用MOG-AB的患者中，有7名（41％）的患者有5例（29％）LETM，4（24％）NMO和1（6％）ADEM。与患有AQP4-AB的患者相比，MOG-AB患者的年龄较小（中位数：27 vs. 40。5年），没有女性占主导地位（53％vs. 90％），临床过程更频繁（41％vs（41％） 。在八名配对血清脊髓液（CSF）样品的患者中，两个样品中有5例Mog-AB，只有三名血清。在临床表型或疾病过程中，抗体滴度没有差异。在12/14例患者（中位随访：23个月）中，MOG-AB仍然可以检测到，而滴度的演变和结果之间没有相关性。
MOG-AB鉴定了与与AQP4-AB相关的NMO，LETM及其结果更好的成年患者的亚组。与CSF相比，在血清中更频繁地检测到MOG-AB，并且滴度的随访与结果无关。
We aimed to report the frequency and implications of antibodies to myelin oligodendrocyte glycoprotein (MOG-ab) in adults with demyelinating syndromes suspicious for neuromyelitis optica (NMO). Samples from 174 patients (48 NMO, 84 longitudinally extensive myelitis (LETM), 39 optic neuritis (ON), and three acute disseminated encephalomyelitis (ADEM) who presented initially with isolated LETM) were retrospectively examined for AQP4-ab and MOG-ab using cell-based assays. MOG-ab were found in 17 (9.8%) patients, AQP4-ab in 59 (34%), and both antibodies in two (1.1%). Among the 17 patients with MOG-ab alone, seven (41%) had ON, five (29%) LETM, four (24%) NMO, and one (6%) ADEM. Compared with patients with AQP4-ab, those with MOG-ab were significantly younger (median: 27 vs. 40.5 years), without female predominance (53% vs. 90%), and the clinical course was more frequently monophasic (41% vs. 7%) with a benign outcome (median Expanded Disability Status Scale: 1.5 vs. 4.0). In eight patients with paired serum-cerebrospinal fluid (CSF) samples, five had MOG-ab in both samples and three only in serum. Antibody titres did not differ among clinical phenotypes or disease course. MOG-ab remained detectable in 12/14 patients (median follow-up: 23 months) without correlation between titres' evolution and outcome. MOG-ab identify a subgroup of adult patients with NMO, LETM and ON that have better outcome than those associated with AQP4-ab. MOG-ab are more frequently detected in serum than CSF and the follow-up of titres does not correlate with outcome.